C. Behrend

No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease

Joseph A. Murray, Ciarán P. Kelly, Peter H.R. Green et al. · Gastroenterology · 2016 · 131 citations · Full text

Difference Between Latiglutenase, Villous Atrophy, Clinical Presentation +3

Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study

Jason A. Tye–Din, A. James M. Daveson, Gautam Goel et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 31 citations

Interim Analysis, Food Intolerance, Bolus Exposure +10

Bile acid-independent bile flow is differently regulated by glucagon and secretin in humans after orthotopic liver transplantation

R. Lenzen, Judith Elster, C. Behrend et al. · Hepatology · 1997 · 24 citations · Full text

Acid-independent Bile Flow, Glucagon Tests, Gastroenterology +20